A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety,
tolerability, and PK of IV administered DAN-222 followed by a dose-escalation of DAN-222 in
combination with niraparib. There are two stages within this study:
Stage 1:
...
Age: 18 years - 66+
Gender: Female
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with
Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Age: 18 - 90 years
Gender: Female
Integrated Intervention for Breast Cancer Survivors With Diabetes
The purpose of this research study is to learn how therapy for breast cancer or DCIS/LCIS affects cognitive function and beliefs about cancer/DCIS/LCIS and diabetes (DM). For this portion of the study, the study team will integrate the information collected at previous ...
Age: 55 years - 66+
Gender: Female
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to
suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The
study will also aim to assess the safety of TOL2506 in men with HR+ breast cancer. ...
Age: 18 - 49 years
Gender: All
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in
participants with HER2-positive primary breast cancer who have received preoperative
chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a
findin...
Age: 18 years - 66+
Gender: All
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects
with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or
relapsed to standard of care (including pembrolizumab, if approved for that indicati...
Age: 18 years - 66+
Gender: All
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a
different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial
have either spread to other parts of the body (metastatic) or cannot be removed c...
Age: 18 years - 66+
Gender: All
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Age: Birth - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate
the efficacy and safety of giredestrant combined with palbociclib compared with letrozole
combined with palbociclib in patients with estrogen receptor (ER)-positive, human ...
Age: 18 years - 66+
Gender: All
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in
preventing breast cancer from coming back (relapsing) in patients with high risk, HER2
positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a
...
Age: 18 years - 66+
Gender: All
Increasing African Immigrant Women's Participation in Breast Cancer Screening
New York City (NYC) is home to a large and diverse immigrant population. Many of these groups
face significant barriers to preventive health care, including lack of insurance, poor health
care access and language difficulties. Most African immigrant women are likely...
Age: 18 - 74 years
Gender: All
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating
further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer
who have no cancer remaining at surgery (either in the breast or underarm lymph node...
Age: 18 years - 66+
Gender: All
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an
engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally
occurring human antibody. The safety, tolerability, PK, and biological activity of...
Age: 18 years - 66+
Gender: All
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site"
of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into
the blood stream (intravenous or "IV").
1. Radiation: The target site --lymph nod...
Age: 18 years - 66+
Gender: All
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses
of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Age: 18 years - 66+
Gender: All
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is
characterized by the lack of expression of estrogen receptor (ER), progesterone receptor
(PR), and HER-2 non-amplification. Women with TNBC tend to be younger, African American, and
...
Age: 18 years - 66+
Gender: Female
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual
care that includes regional radiation therapy, with receiving no regional radiation therapy.
Researchers want to see if not giving this type of radiation treatment works as...
Age: 35 years - 66+
Gender: Female
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast cancer patients. In this phase I/II clinical trial, the researchers aim to es...
Age: 18 years - 66+
Gender: All
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase inhibitor plus a CDK4/6 inhibitor (either palbociclib or ribociclib) to eith...
Age: 18 years - 66+
Gender: All
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared
to the combination of carboplatin and everolimus for the treatment of advanced
triple-negative breast cancer (TNBC).
Age: 18 years - 66+
Gender: Female